Viralgen is streamlining gene therapy manufacturing with a platform approach that accelerates timelines and reduces complexity. By leveraging process knowledge across multiple AAV serotypes, we enable faster production while ensuring quality and compliance at every stage.
Our HEK-293 suspension cell line (Pro25™) and optimized process workflows allow us to scale efficiently from research to GMP, helping gene therapy developers bring life-changing treatments to patients sooner.
Explore more in our poster: “Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen.”
